Compositions of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Pharmaceutical compositions including N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) and methods of using such compositions are described herein.
1. A pharmaceutical composition comprising: N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide; PEG 400; and PVP K30.
2. The pharmaceutical composition according to claim 1 , wherein said N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide is present in an amount between about 0.01% w/w to about 6.5% w/w.
3. The pharmaceutical composition according to claim 1 , wherein said PEG is present in an amount between about 87.5% w/w to about 99.99% w/w.
4. The pharmaceutical composition according to claim 1 , wherein said PVP K30 is present in an amount between 0% w/w to about 6% w/w.
5. The pharmaceutical composition according to claim 1 , wherein said composition comprises PEG 400 (97.88% w/w), PVP K30 (2.0% w/w), and N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (0.13% w/w).
6. The pharmaceutical composition according to claim 1 , wherein said composition comprises PEG 400 (97.75% w/w), PVP K30 (2.0% w/w), and N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (0.25% w/w).
7. The pharmaceutical composition according to claim 1 , wherein said composition comprises PEG 400 (97.5% w/w), PVP K30 (2.0% w/w), and N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (0.5% w/w).
8. The pharmaceutical composition according to claim 1 , wherein said composition comprises PEG 400 (97.0% w/w), PVP K30 (2.0% w/w), and N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (1.0% w/w).
9. The pharmaceutical composition according to claim 1 , wherein said composition comprises PEG 400 (96.63% w/w), PVP K30 (2.0% w/w), and N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (1.38% w/w).
10. The pharmaceutical composition according to claim 1 , wherein said composition comprises PEG 400 (96.13% w/w), PVP K30 (2.0% w/w), and N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (1.88% w/w).
11. The pharmaceutical composition according to claim 1 , wherein said composition comprises PEG 400 (95.75% w/w), PVP K30 (2.0% w/w), and N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (2.25% w/w).
12. The pharmaceutical composition according to claim 1 , wherein said composition comprises PEG 400 (95.5% w/w), PVP K30 (2.0% w/w), and N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (2.5% w/w).
13. The pharmaceutical composition according to claim 1 , wherein said composition comprises PEG 400 (94.63% w/w), PVP K30 (2.0% w/w), and N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (3.38% w/w).
14. The pharmaceutical composition according to claim 1 , wherein said composition comprises PEG 400 (94.0% w/w), PVP K30 (2.0% w/w), and N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (4.0% w/w).
15. A method of treating a CFTR mediated disease in a patient comprising the step of administering to said patient a pharmaceutical composition according to claim 1 .
16. The method according to claim 15 , wherein said disease is selected from cystic fibrosis, hereditary emphysema, hereditary hemochromatosis, a coagulation-fibrinolysis deficiency, Type 1 hereditary angioedema, a lipid processing deficiency, a lysosomal storage disease Crigler-Najjar type II, polyendocrinopathy/hyperinsulinemia, Diabetes mellitus, Laron dwarfism, myleoperoxidase deficiency, primary hypoparathyroidism, melanoma, glycanosis CDG type 1, hereditary emphysema, congenital hyperthyroidism, osteogenesis imperfecta, hereditary hypofibrinogenemia, ACT deficiency, Diabetes insipidus (DI), neurophyseal DI, neprogenic DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease, a neurodegenerative disease a polyglutamine neurological disorder, orders a spongiform encephalopathy, Fabry disease, Straussler-Scheinker syndrome, COPD, dry-eye disease and Sjogren's disease.
17. The method according to claim 16 , wherein said disease is cystic fibrosis.
18. The method according to claim 15 , wherein said pharmaceutical composition is administered to a patient in need thereof once a day.
19. The method according to claim 16 wherein the coagulation-fibrinolysis deficiency is protein C deficiency.
20. The method according to claim 16 wherein the lipid processing deficiency is familial hypercholesterolemia, Type 1 chylomicronemia or abetalipoproteinemia.
21. The method according to claim 16 wherein the lysosomal storage disease is I-cell disease, pseudo-Hurler, mucopolysaccharidoses, Sandhoff disease, or Tay-Sachs.
22. The method according to claim 16 wherein the neurodegenerative disease is Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear palsy, or Pick's disease.
23. The method according to claim 16 wherein the polyglutamine neurological disorder is Huntington's disease, spinocerebullar ataxia type I, spinal muscular atrophy, bulbar muscular atrophy, dentatorubal pallidoluysian, or myotonic dystrophy.
24. The method according to claim 16 wherein the spongiform encephalopathy is hereditary Creutzfeldt-Jakob disease.